Compare Boston Beer Company Inc (SAM) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Beer Company Inc vs Zimmer Biomet Holdings Inc — how do they compare? Boston Beer Company Inc trades at $170.75 (market cap $1.88B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9.2× Boston Beer Company Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Boston Beer Company Inc pays none. Which is the better fit depends on your goals.
| SAM | ZBH | |
|---|---|---|
Market Cap | $1.88B | $17.36B |
Sector | Consumer Staples | Health |
52-Week High | $260.05 | $107.71 |
52-Week Low | $161.08 | $79.58 |
Enterprise Value | $1.75B | $24.40B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Beer Company (SAM) trades at $170.98, down 4.37% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. Fundamentally, the company reported strong 2025 results with $108M net income and positive cash flow, though 2026 projections show potential challenges with expected revenue decline and negative margins. Recent earnings show a mix of beats and misses, with Q2 2026 results pending.
The stock presents a cautious opportunity with analyst consensus target of $204.33 suggesting 19% upside, but faces headwinds from declining volumes, competitive pressure in hard seltzer market, and negative FY26 EPS growth projections. Institutional sentiment leans neutral with 74% hold ratings, reflecting balanced risk-reward amid evolving consumer beverage preferences.
Zimmer Biomet (ZBH) trades at $88.92, down 2.41% on the day, with a bearish technical signal but strong fundamentals including a 70.03% gross margin and three consecutive quarterly EPS beats. Revenue grew to $8.23B in 2025, though net income margin compressed to 8.56%. The company announced a $1 billion share repurchase increase and expansion in India, while maintaining a dividend.
The stock offers a 10% upside to the $97.67 consensus price target, supported by value metrics and operational strength, but faces risks from rising debt levels and competitive pressures. Analyst sentiment is mixed with 40% buy ratings, suggesting cautious optimism amid near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Beer Company Inc
Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.
Read more on SAM →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
